These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33479623)

  • 1. New chemical agents based on adamantane-monoterpene conjugates against orthopoxvirus infections.
    Suslov EV; Mozhaytsev ES; Korchagina DV; Bormotov NI; Yarovaya OI; Volcho KP; Serova OA; Agafonov AP; Maksyutov RA; Shishkina LN; Salakhutdinov NF
    RSC Med Chem; 2020 Oct; 11(10):1185-1195. PubMed ID: 33479623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of esters and amides of 2-aryl-1-hydroxy-4-methyl-1H-imidazole-5-carboxylic acids and study of their antiviral activity against orthopoxviruses.
    Nikitina PA; Basanova EI; Nikolaenkova EB; Os'kina IA; Serova OA; Bormotov NI; Shishkina LN; Perevalov VP; Tikhonov AY
    Bioorg Med Chem Lett; 2023 Jan; 79():129080. PubMed ID: 36414175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design, Synthesis, and Biological Evaluation of the Cage-Amide Derived Orthopox Virus Replication Inhibitors.
    Mozhaitsev ES; Suslov EV; Rastrepaeva DA; Yarovaya OI; Borisevich SS; Khamitov EM; Kolybalov DS; Arkhipov SG; Bormotov NI; Shishkina LN; Serova OA; Brunilin RV; Vernigora AA; Nawrozkij MB; Agafonov AP; Maksyutov RA; Volcho KP; Salakhutdinov NF
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adamantane derivatives as potential inhibitors of p37 major envelope protein and poxvirus reproduction. Design, synthesis and antiviral activity.
    Shiryaev VA; Skomorohov MY; Leonova MV; Bormotov NI; Serova OA; Shishkina LN; Agafonov AP; Maksyutov RA; Klimochkin YN
    Eur J Med Chem; 2021 Oct; 221():113485. PubMed ID: 33965861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Cytotoxicity and Antiviral Activity Against Vaccinia Virus of 2-(3-Coumarinyl)-1-Hydroxyimidazoles.
    Nikitina PA; Zakharova AM; Serova OA; Bormotov NI; Mazurkov OY; Shishkina LN; Koldaeva TY; Basanova EI; Perevalov VP
    Med Chem; 2023; 19(5):468-477. PubMed ID: 36437720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
    Quenelle DC; Collins DJ; Kern ER
    Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox.
    Brown LE; Seitz S; Kondas AV; Marcyk PT; Filone CM; Hossain MM; Schaus SE; Olson VA; Connor JH
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0084122. PubMed ID: 36222522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus.
    Olson VA; Laue T; Laker MT; Babkin IV; Drosten C; Shchelkunov SN; Niedrig M; Damon IK; Meyer H
    J Clin Microbiol; 2004 May; 42(5):1940-6. PubMed ID: 15131152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
    Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
    J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
    Smee DF
    Antivir Chem Chemother; 2008; 19(3):115-24. PubMed ID: 19024628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse models for studying orthopoxvirus respiratory infections.
    Schriewer J; Buller RM; Owens G
    Methods Mol Biol; 2004; 269():289-308. PubMed ID: 15114022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals.
    Grosenbach DW; Hruby DE
    Methods Mol Biol; 2019; 2023():143-155. PubMed ID: 31240676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antiviral activity of camphor-based 1,3-thiazolidin-4-one and thiazole derivatives as
    Sokolova AS; Yarovaya OI; Bormotov NI; Shishkina LN; Salakhutdinov NF
    Medchemcomm; 2018 Oct; 9(10):1746-1753. PubMed ID: 30429979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
    Keith KA; Hitchcock MJ; Lee WA; Holý A; Kern ER
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
    Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
    Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents.
    Sokolova AS; Kovaleva KS; Yarovaya OI; Bormotov NI; Shishkina LN; Serova OA; Sergeev AA; Agafonov AP; Maksuytov RA; Salakhutdinov NF
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2100038. PubMed ID: 33605479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
    Kern ER; Prichard MN; Quenelle DC; Keith KA; Tiwari KN; Maddry JA; Secrist JA
    Antimicrob Agents Chemother; 2009 Feb; 53(2):572-9. PubMed ID: 19029322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Biological Evaluation of (+)-Camphor- and (-)-Fenchone-Based Derivatives as Potent Orthopoxvirus Inhibitors.
    Sokolova AS; Kovaleva KS; Kuranov SO; Bormotov NI; Borisevich SS; Zhukovets AA; Yarovaya OI; Serova OA; Nawrozkij MB; Vernigora AA; Davidenko AV; Khamitov EM; Peshkov RY; Shishkina LN; Maksuytov RA; Salakhutdinov NF
    ChemMedChem; 2022 Jun; 17(12):e202100771. PubMed ID: 35388614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.
    Smee DF
    Future Virol; 2013 Sep; 8(9):891-901. PubMed ID: 24563659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.